Comments
Drugmaker Glenmark Pharmaceuticals has said that its prospective novel drug GBR 830, for the treatment of auto-immune diseases, is entering human trials.
The company has completed the first phase of enabling preclinical development program for GBR 830 and has filed a Phase-I clinical trial application with authorities in the Netherlands, the company said. Drug molecules are tested on human volunteers to test for safety and efficacy of the monoclonal antibody, in this case. GBR 830 targets auto-reactive T cells.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.